top of page
  • Writer's pictureRCS Ottawa

Mobile innovation will help 2 billion more people get access to healthcare and education

From music to movies, from banking to buying food, mobile phones have revolutionized the way we access the world today. But for low-income consumers in emerging markets, the full potential of mobile financial services is yet to be unlocked, a new report suggests.

Despite the growth in smartphone adoption and mobile payment systems in many countries, telecom operators and regulators were yet to invest in products and distribution models that would cater for largely underserved or unbanked consumers. The report from Swedish insurance technology company BIMA surveyed 4,000 low-income respondents in 10 countries across Africa, Asia, and Latin America. BIMA notes that the lack of synergy between regulators and operators in emerging markets has also undermined the development of mobile solutions for complex services such as healthcare, insurance, and savings.

In emerging markets, formal banking reaches about 37% of the population, compared with a 50% penetration rate for mobile phones financial systems, according to global management consultancy McKinsey. This constitutes 2.2 billion adults who don’t use banks or micro-financial institutions in the world—more than 326 million of whom live in Sub-Saharan Africa. If companies are able to successfully tap into these unbanked consumers, that will constitute a “second wave” of mobile financial services, where customers move beyond using mobile as a channel for just payments.

3 views0 comments

Recent Posts

See All

Commonwealth Youth Profile - Aniqah Zowmi

Canadian Aniqah Zowmi brings expertise and passion for helping governments and civic organisations embrace equality and diversity and achieve full inclusion at levels. She is currently the director of

mRNA the innovation behind Pfizer and Moderna vaccines

Messenger RNA (mRNA) is a pivotal molecule of life, involved in almost all aspects of cell biology. The last decade has seen improvements in the delivery of a new class of mRNA drugs. In molecular bi

bottom of page